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Abstract: Flavonoids are natural biomolecules that are known to be effective antivirals. These 
biomolecules can act at different stages of viral infection, particularly at the molecular level to inhibit 
viral growth. Enterovirus A71 (EV-A71), a non-enveloped RNA virus, is one of the causative agents of 
hand, foot and mouth disease (HFMD), which is prevalent in Asia. Despite much effort, no clinically 
approved antiviral treatment is available for children suffering from HFMD. Flavonoids from plants 
serve as a vast reservoir of therapeutically active constituents that have been explored as potential 
antiviral candidates against RNA and DNA viruses. Here, we reviewed flavonoids as evidence-based 
natural sources of antivirals against non-picornaviruses and picornaviruses. The detailed molecular 
mechanisms involved in the inhibition of EV-A71 infections are discussed. 
Keywords: flavonoids; antivirals; Enterovirus 71 (EV-A71); infectious childhood disease; hand, foot 
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1. Introduction 
Flavonoids are naturally occurring polyphenolic biomolecules widely found in plants and are 
responsible for a wide variety of biological functions [1]. Pharmacological properties of flavonoids 
include antioxidant, anti-inflammatory, anticancer, antimicrobial and immunomodulatory functions 
[2]. More than 6000 compounds have been identified as flavonoids based on their basic structures 
consisting of C6-C3-C6 and they are divided into several classes such as flavonols, flavanones, 
isoflavones, flavones, and anthocyanidins. Due to a wide range of biological activities being exhibited 
by flavonoids, they have become molecules of interest for natural drug discovery research. In this 
review, antiviral mechanisms of flavonoids, mainly against Enterovirus A-71 (EV-A71), will be discussed 
to provide evidence-based efficacy of antiviral properties. 
2. Flavonoids against Viruses 
Flavonoids have been studied against a wide range of DNA and RNA viruses. In general, 
flavonoids work by several mechanisms. They can block attachment and entry of viruses into cells, 
interfere with various stages of viral replication processes or translation and polyprotein processing to 
prevent the release of the viruses to infect other cells. Different flavonoids have been found to inhibit 
the virus through various mechanisms. Based on antiviral mechanisms of action, flavonoids can be 
prophylactic inhibitors, therapeutic inhibitors or indirect inhibitors by interaction with the immune 
system. Flavonoids that inhibit viral activity can be further divided into the following sub-categories. 
 Flavonoids that bind to specific extracellular regions of the virus such as viral proteins present on 
the capsids. 
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 Flavonoids that prevent attachment or entry of the virus into host cells. In some cases, flavonoids 
can bind to virions and modify the virus structure. Though the virus can still internalize, the 
process of viral uncoating is stalled. 
 Early-stage replication inhibitors. 
 Transcription and translation blockers. 
 Inhibition of late stages of maturation such as inhibition of assembly/packaging and release. 
 Flavonoids that can inhibit viral infections by interfering with host factors that are required for 
successful infection or modulating the immune system to reduce the viral load. 
2.1. Flavonoids against Non-Picornaviruses 
Research has been carried out on plants that are being used in traditional medicines in different 
parts of the world. Many natural compounds of various chemical classes have been identified as 
potential therapeutic agents. Several flavonoids have been studied to evaluate their antiviral potential. 
For example, quercetin and quercitrin were first demonstrated by Cutting et al. (1949) to 
prophylactically inhibit rabies virus in mice [3]. Moreover, quercetin was found to exhibit its antiviral 
activity against vesicular stomatitis virus (VSV) by activation of macrophages [4]. Biologically active 
components of Elderberry extract dihydromyricetin and tetra-O-methyl quercetin were found to inhibit 
influenza A virus in vitro, most likely by binding to viral mannose-rich hemagglutinin domains which 
are important for the virus to enter the host cells [5]. Mechanistic studies later showed that it was able 
to inhibit neuraminidase activity of influenza A virus by interaction with the subunit 2 of the 
hemagglutinin that resulted in virus entry inhibition [6]. Quercitrin, a rhamnoside derivative of 
quercetin, was found to inhibit the initial stage of viral replication of the influenza A virus, evident by a 
decrease in mRNA synthesis of the virus. The study also concluded that quercitrin was unable to 
interact directly with virus particles [7]. Quercetin was shown to inactivate the NS3 helicase and NS5 
protease of hepatitis C virus (HCV) [8,9]. Quercetin also blocked viral binding and entry of herpes simplex 
virus (HSV)-1, HSV-2, and drug-resistant HSV-1 to Madin–Darby canine kidney NBL-2 (MDCK) cells 
[6]. Another flavonoid derivative, 3-β-O-D-glucoside, was able to protect mice from Ebola virus infection 
when given prior to virus challenge. However, the mechanism by which this flavonoid inhibited viral 
entry is unclear [10]. 
In a similar manner, sulfated rutin was shown to block the entry of human immunodeficiency viruse 
(HIV)-1 without interactions with the host cell membrane. Cell fusion and entry assays revealed that 
sulfated rutin could drastically inhibit HIV-1 infection when cells were treated during the early 
adsorption phase. The probable mechanism proposed by investigators was the inhibition of HIV 
glycoprotein-mediated cell-cell fusion step [11]. In the same study, it was identified that sulfated rutin 
could also inhibit HSV, the mechanism of inhibition is still unknown. 
Apigenin was reported as an antiviral against HCV by host factor modulation. It caused a 
reduction in mature miRNA122 production that regulated HCV infection in vitro [12]. Baicalin was 
found to interfere with the interaction between the HIV-1 envelope protein and host immune cells. This 
anti-HIV activity was achieved by inhibition of the HIV-1 envelope glycoprotein (gp120)-mediated 
fusion with T cells and monocytes expressing CD4/CXCR4 or CD4/CCR5 [13]. In addition, baicalin was 
also reported to inhibit dengue virus (DENV-2) by the virucidal mechanism. It blocked the attachment 
of DENV-2 to the Vero cells but did not show any activity during the virus entry stage [14]. Baicalin 
was able to induce the production of interferon-gamma (IFN-ɣ) in natural killer (NK), CD4+ and CD8+ 
T cells during in vitro influenza A virus infection. It was suggested that baicalin was able to directly bind 
NS1–p85β (RNA binding domain), which was the main mediator to downregulate IFN-ɣ [15]. The 
induction of IFN-ɣ triggered the immune system to activate the Janus kinase/signal transducer and 
activator of transcription protein 1 (JAK/STAT1) pathway, which led to the expression of IFN-ɣ-
inducible genes. This expression of IFN-ɣ genes and signaling pathway facilitated the reduction of viral 
loads by immune modulation [16]. Baicalein, the parent compound of baicalin, has also been reported 
as antiviral against Japanese encephalitis virus (JEV) and DENV-2. It is postulated that baicalein inhibited 
JEV by probable interaction with structural proteins of virus and this prevented entry of the virus into 
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the cells [17]. However, the antiviral mechanism against DENV-2 was identified as replication 
inhibition in silico by interaction with viral NS3/NS2B and NS5 proteins [18]. 
Flavonoids, genistein and ginkgetin, were reported to inhibit assembly and release of HIV and 
influenza A virus, respectively. Genistein inhibited Vpu protein that is involved in the formation of ion 
channels in infected cells and thus controlled the release of HIV [19]. Ginkgetin inhibited sialidase 
activity of influenza A virus and thus inhibited virus assembly and release [20]. Fisetin possessed post-
infection anti-CHIKV activity by the inhibition of NS proteins 1 and 3 in a dose-dependent manner. 
Moreover, it was observed that CHIKV E2 protein and its precursor pE2 were also downregulated 
during treatment with fisetin [21]. Similarly, a decreased replication process of DENV-2 was observed 
when Vero cells were treated with fisetin after DENV-2 infection. It was postulated that this antiviral 
activity could be due to the direct binding of fisetin to the viral RNA, thus impeding polymerase activity 
[22]. Kaempferol and its structural flavonol derivatives were studied to identify the suitable 
pharmacophore to design antiviral against the influenza A virus. This study revealed that most of the 
flavonols with structural similarity with kaempferol were able to noncompetitively inhibit 
neuraminidase enzyme. However, the exact interacting partner is still unknown [23]. Moreover, 
kaempferol was also reported to inhibit 3a channels of coronavirus and blocked the release of virus 
progeny [24]. Luteolin was found to interfere with the entry of influenza A virus and severe acute 
respiratory syndrome coronavirus (SARS-CoV) by interacting with hemagglutinins of influenza A virus and 
S2 protein of SARS CoV viruses, respectively [25,26]. 
Another group of flavonoids, viz. methoxyflavone, isoscutellarein, and 8-methoxy-isoscutellarein, 
were reported to inhibit early replication of influenza A virus by reduction of sialidase activity, inhibition 
of lysosomal fusion and RNA polymerase activity [27]. Naringenin, a flavanone, also possessed 
antiviral activities against HCV [28], DENV-2, DENV-4 [29] and CHIKV [30] by replication inhibition at 
RNA and protein levels. Other flavonoid such as silymarin which has a broad-spectrum antiviral 
activity [31-33] was able to block entry and fusion of HCV viral pseudo-particles (pp) when Huh-7.5 
cells were pre-treated with silymarin [34]. Moreover, it was shown to interfere with the replication 
process of DEN-V, CHIKV and influenza A virus [35-37]. 
Tea catechins were also reported to inhibit the influenza A virus by binding to the hemagglutinins 
and restricted virus adsorption, preventing the penetration of the virus into the cells [38]. Tea catechins 
were studied in clinical trials by Matsumoto and co-workers (2011). They conducted a randomized 
controlled trial to study the effects of tea catechins in the prevention of influenza virus infections in 
healthcare workers in elderly homes. Tea catechins were effective in preventing the clinical incidence 
of influenza infections in the treatment group as compared to the placebo group [39]. Epigallocatechin 
(EGC), a tea catechin flavonoid, was reported to inhibit the replication of influenza A and B viruses by 
in vitro acidification of the lysosomal and endosomal environment through clathrin-mediated 
endocytosis [40]. Apart from having antiviral activity against the influenza virus, another flavonoid 
from tea catechins, epigallocatechin gallate (EGCG), was shown to directly bind to CD4+ T-cells. This 
binding blocked the binding of the HIV-1 envelope protein (gp120) and caused viral entry inhibition 
[41]. EGCG was also demonstrated to bind to the glycoprotein B and glycoprotein D of HSV to render 
it non-infective [42]. Moreover, EGCG was shown to have potent antiviral activity against CHIKV by 
blocking its entry, probably by competing for cellular co-receptors of target cells such as heparan sulfate 
or sialic acid [43]. EGCG was also found to inhibit the replication of Epstein–Barr virus (EBV) by 
inhibition of Zta, Rta and EA-D genes. This inhibition interrupted the MEK/ERK1/2 and PI3-K/Akt 
signaling pathway of the lytic cycle EBV [44]. EGCG also inhibited hepatitis B virus (HBV) replication by 
impairment of the production of pre-core mRNA and replicative intermediates of DNA [45]. Zika virus 
was also inhibited by EGCG, as it was able to interact with the lipid envelope and blocked the entry of 
virus into cells [46]. It also caused acidification in lysosomes to make an unfavorable environment for 
virus replication [47]. The antiviral activities of several other flavonoids according to the mechanisms 
of inhibition against various viruses are summarized in Table 1. Structures of these flavonoids can be 
found in Supplementary material Table S1: Molecular structures of antiviral flavonoids.
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Table 1. Examples of antiviral flavonoids against non-picornaviruses. 
Flavonoid Virus Virus Family Model 
Stage of Virus 
Inhibition 
Suggested Mechanism Reference 
Apigenin 
Hepatitis C virus 
(HCV) 
Flaviviridae In vitro 
Host factor 
modulation 
Reduction in mature miRNA122 [12] 
Baicalin 
Dengue virus-2 
(DENV-2) 
Flaviviridae In vitro Attachment 
Blockade of attachment of the virus to 
Vero cells 
[14] 
 
Human 
immunodeficiency 
virus-1 (HIV-1) 
Retroviridae In vitro Fusion 
Inhibition of the fusion of virus envelope 
protein with T cells and monocytes 
expressing CD4/CXCR4 or CD4/CCR5 
[13] 
 Influenza A virus Orthomyxoviridae In vitro 
Indirect: Immune-
mediated 
infection control 
Directly binds to NS1–p85β (RNA 
binding domain) to down-regulate IFN-ɣ 
and activates the JAK/STAT1 pathway 
that reduced the viral load 
[15,16] 
Baicalein 
Chikungunya virus 
(CHIKV) 
Togaviridae In vitro Prophylaxis 
Inhibition of attachment by inhibiting 
extracellular particles such as nsP1, nsP3, 
and E2 proteins 
[21] 
 DENV-2 Flaviviridae In silico Replication Binds to the NS3/NS2B and NS5 proteins [18] 
 
Japanese encephalitis 
virus (JEV) 
Flaviviridae In vitro Entry 
Unknown 
Postulated to be an accumulation of the 
compound in cells to prevent entry or 
interaction with structural and/or non-
structural protein(s) 
[17] 
Epigallocatechin 
(ECG) 
Influenza A and B 
viruses 
Orthomyxoviridae In vitro Replication 
Acidification of the lysosomal and 
endosomal environment through 
clathrin-mediated endocytosis 
[40] 
Epigallocatechin 
gallate (EGGC) 
CHIKV Togaviridae In vitro Entry 
Competitor for cellular co-receptors of 
target cells such as heparan sulfate or 
sialic acid 
[43] 
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Epstein–Barr virus 
(EBV) 
Herpesviridae  Replication 
Inhibition of Zta, Rta and EA-D genes by 
interrupting the MEK/ERK1/2 and PI3-
K/Akt signaling pathway of the lytic 
cycle of a virus 
[44] 
 
Hepatitis B virus 
(HBV) 
Hepadnaviridae In vitro Replication 
Impair the production of pre-core mRNA 
and replicative intermediates of DNA 
[45] 
Acidification in lysosomes to make an 
unfavorable environment for virus 
replication 
[47] 
 
Herpes simplex virus 
(HSV) 
Herpesviridae In vitro Entry Binds to glycoprotein B and D of virus [42] 
 HIV-1 Retroviridae In vitro Entry 
Directly binds to CD4+ T-cells and blocks 
binding of envelope protein gp120 to 
cells 
[41] 
 Zika virus Flaviviridae In vitro Entry 
Interaction with the lipid envelope of 
virus 
[46] 
Fisetin CHIKV Togaviridae In vitro Replication 
Inhibition of NS protein 1 and 3 and 
downregulation of E2 protein and its 
precursor pE2 
[21] 
 DENV-2 Flaviviridae In vitro Replication 
Directly binds to the viral RNA to 
impede polymerases activity 
[22] 
Genistein HIV Retroviridae In vitro 
Assembly and 
release 
Inhibition of Vpu protein involved in the 
formation of ion channels in infected cells 
[19] 
Ginkgetin Influenza A virus Orthomyxoviridae In vitro 
Assembly and 
release 
Inhibition of sialidase [20] 
Kaempferol Coronavirus Coronaviridae In vitro 
Assembly and 
release 
Inhibition of the release of progeny virus 
by blocking 3a channels of virus 
[24] 
 Influenza A virus Orthomyxoviridae In silico Entry Inhibition of neuraminidase enzyme [23] 
Luteolin Influenza A virus Orthomyxoviridae In vitro Entry Interaction with hemagglutinins of virus [25] 
 
Severe acute respiratory 
syndrome coronavirus 
(SARS-CoV) 
Coronaviridae In vitro Entry Binds to the S2 protein of virus [25] 
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Methoxyflavone, 
isoscutellarein, and 8-
methoxy-
isoscutellarein 
Influenza A virus Orthomyxoviridae In vitro Early replication 
Reduction in sialidase activity, lysosomal 
fusion and RNA polymerase activity 
[27,48] 
Naringenin CHIKV Togaviridae In vitro Replication Reduction in RNA and proteins [49] 
 DENV-2 and 4 Flaviviridae In vitro Replication Reduction in RNA levels [29,30] 
 HCV Flaviviridae In vitro Replication Inhibition of RNA and core protein [28] 
Quercetin HCV Flaviviridae In vitro Transcription 
Inactivation of the NS3 helicase and NS5 
protease 
[8,9] 
 
HSV-1, HSV-2, drug-
resistant HSV-1 
Herpesviridae In vitro Binding and entry N/R [6] 
 Influenza A virus Orthomyxoviridae In vitro Binding and entry 
Inhibition of neuraminidase activity by 
interaction with the viral subunit 2 of the 
hemagglutinin 
[6] 
 Rabies virus Rhabdoviridae In vivo Cell protection N/R [3] 
 
Vesicular stomatitis 
virus (VSV) 
Rhabdoviridae In vivo 
Indirect: Immune-
mediated 
infection control 
Activation of macrophages [4] 
Quercetin 3-β-O-D-
glucoside 
Ebola virus Filoviridae In vivo Prophylaxis Unknown [10] 
Quercitrin Influenza A virus Orthomyxoviridae In vitro Early replication Reduction in mRNA synthesis [7] 
 Rabies virus Rhabdoviridae In vivo Prophylaxis Unknown [3] 
Rutin (sulfated) HIV-1 Retroviridae In vitro Fusion 
Inhibition of glycoprotein-mediated cell-
cell fusion 
[11] 
 HSV Herpesviridae In vitro Adsorption Unknown [11] 
Silibinin HCV Flaviviridae 
Phase II 
Clinical 
trial 
Replication or 
immune-
mediated 
infection control 
Unknown. 
Postulated to be IFN-JAK/STAT 
independent immune-mediated antiviral 
mechanisms such as Regulation by 
interferon regulatory factor 3, Toll-like 
receptor 7 and p38 protein kinase 
pathways 
[31] 
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Silymarin CHIKV Togaviridae In vitro Replication Inhibition of viral proteins [35] 
 DENV-2 Flaviviridae In silico Replication Inhibition of NS4B protein [36] 
 EBV Herpesviridae In vitro 
Early antigen 
inactivation 
N/R [32] 
 HCV Flaviviridae In vitro Entry and fusion 
Inhibition of viral pseudoparticles (pp) 
fusion with liposomes 
[34] 
 Influenza A virus Orthomyxoviridae In vitro Late replication Inhibition of viral mRNA synthesis [37] 
 Mayaro virus Togaviridae In vitro Replication 
Inhibition of reactive oxygen species 
(ROS) and reduction in levels of 
malondialdehyde (MDA) 
[33] 
Tea catechins Influenza A virus Orthomyxoviridae In vitro 
Adsorption and 
entry 
Interaction with hemagglutinins of virus  [38] 
Tetra-O-methyl 
quercetin 
Influenza A virus Orthomyxoviridae In vitro Entry 
Interaction with mannose-rich 
hemagglutinin domains of virus 
[5] 
N/R = not reported, NS = nonstructural. Structures of flavonoids are provided in Supplementary Materials Table S1.
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2.2. Flavonoids against Non-EV-A71 Picornaviruses 
Picornaviruses are non-enveloped RNA viruses belonging to the picornaviridae family. Their 
natural hosts are vertebrates such as reptiles, fish, amphibians, birds and mammals. Viral infections 
such as poliomyelitis, hepatitis A, common cold and hand, foot and mouth disease are caused by 
picornaviruses. Flavonoids, in particular, have shown promising results in the laboratory against 
picornaviruses. Some of these flavonoids are discussed. 
Quercetin, a well-studied flavonoid, exhibited anti-rhinoviral (RV) activity by inhibition of the 
viral transcription and translation processes. Quercetin decreased endocytosis of RV and reduced 
phosphorylation of Akt (effector of phosphoinositol 3-kinase) when epithelial cells were pretreated 
with quercetin. In addition, it also reduced viral infection when added 6 h post-infection in vitro. 
Moreover, it also repressed interferon and interleukin-8 response, resulting in lower viral RNA and 
capsid protein production. Quercetin demonstrated similar effects in vivo with decreased viral loads 
and suppression of viral immune mediators [50]. Quercetin was shown to protect mice when 
challenged with the quercetin-treated Mengo virus. It was interesting to note that there was no 
antiviral activity detected when quercetin was tested in L-929 cells [3]. This observation led to the 
study of the role of interferon induction in antiviral activity. However, there was no significant 
detection of interferons in drug-treated mice. This resulted in speculating that the antiviral activity 
was achieved by macrophage activation instead of interferon induction. In the same study, quercetin 
was also found to inhibit encephalomyocarditis virus (EMCV) by macrophage activation [4]. A methyl 
derivative of quercetin was shown to inhibit poliovirus by blocking the synthesis of viral genomic 
RNA and proteins [51,52]. Similarly, trimethylquercetin was shown to inhibit the production of 
progeny coxsackievirus B4 (CV-B4) and protected the mice from death upon lethal challenge [53]. In 
another independent study, dihydroquercetin isolated from Larix sibirica was found to mediate the 
in vivo CV-B4 infection by inhibition of ROS induced oxidative stress [54]. 
Similarly, luteolin and its derivatives have been studied against picornaviruses. For example, 
luteolin was found to inhibit the RNA synthesis of Coxsackievirus A16 (CV-A16) [55]. Moreover, it was 
also reported to inhibit poliovirus at replication stage. However, the mechanism of inhibition of 
poliovirus by luteolin is still unknown [56]. In contrast to luteolin, its derivative eupafolin was shown 
to inhibit CV-A16 by inhibition of viral attachment. It was shown to reduce the IL-6 and RANTES 
which led to the inactivation of virus-induced upregulated the ERK1/2, c-Jun, and STAT3 signaling 
pathways [57]. 
In a similar manner, kaemferol and its derivatives were also identified to be potent inhibitors of 
picornaviruses. Methylkaempferol was reported to inhibit the late replication step of the poliovirus. 
The inhibition mechanism is attributed to the potential of this flavonoid to inhibit the positive-strand 
synthesis of viral RNA [58]. Furthermore, Kaempferol-3-O-[2″,6″-di-O-Z-p-coumaroyl]-β-D-
glucopyranoside and its derivatives were identified as replication inhibitors of Rhinovirus 1B (HRV-
1B) and Coxsackievirus B3 (CV-B3) in vitro [59]. The group of methoxy flavones were reported to 
inhibit poliovirus-1 by downregulation of signaling pathway and apoptosis [60]. Furthermore, entry 
of rhinovirus was shown to be inhibited in silico by inhibition of the protein grid of virus [61]. 
Another flavonoid sakuranetin was also identified as a potent inhibitor of rhinovirus-3 by its 
antioxidant properties [62]. Several other flavonoids were reported to inhibit the activity of various 
picornaviruses [60,63-66]. However, their exact molecular mechanisms of actions are still unknown. 
Examples of bioflavonoids from various chemical classes exhibiting antiviral activities against 
picornaviruses are summarized in Table 2. Structures of these flavonoids can be found in 
Supplementary material Table S1: Molecular structures of antiviral flavonoids.
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Table 2. Examples of antiviral flavonoids against picornaviruses. 
Flavonoid Picornavirus Model 
Stage of Virus 
Inhibition 
Suggested Mechanism Reference 
3-Methylquercetin 
Poliovirus In vitro Late replication 
Blocked of genomic RNA synthesis [51] 
 Reduction in viral protein and RNA synthesis [52] 
3-Methylkaempferol Poliovirus-1 In vitro Replication Inhibition of positive-strand of viral RNA [58] 
5,3′-Dihydroxy-3,6,7,8,4′-
pentamethoxyflavone and 5-
hydroxy-3,6,7,3′,4′-
pentamethoxyflavone 
Poliovirus-1 In vitro Replication 
Postulated to be inhibition of cellular processes 
(apoptosis and downstream signaling pathways) 
[67] 
5,7,4′-Trihydroxy-3′-
methoxyflavone 
Rhinovirus  
(HRV) 
In silico Entry 
Inhibition by binding to human rhinovirus protein 
grid 
[61] 
6-Chloro-4′-oxazolinylflavanone Poliovirus-2 In vitro Replication N/R [63] 
 HRV-1B In vitro Replication N/R [63] 
7-O-galloyltricetifavan and 7,4′-
di-Ogalloyltricetifavan 
Coxsackievirus B3 
(CV-B3) 
In vitro N/R N/R [64] 
Chrysosplenol C Poliovirus In vitro Replication N/R [65] 
Desmanthin-1 
Coxsackieviruses A16 
(CV-A16) 
In vitro Replication N/R [66] 
Dihydroquercetin 
Coxsackievirus B4 
(CV-B4) 
In vivo 
Indirect: Immune-
mediated infection 
control 
Reduction in viral immune mediators (ROS-
mediated signaling and oxidative stress 
[54] 
Epigallocatechin-3-Gallate Poliovirus-1 In vitro 
Virucidal effect 
(irreversible) 
N/R [60] 
Eupafolin CV-A16 In vitro Attachment 
Reduction in IL-6 and RANTES and inactivation of 
downstream signaling pathways (ERK1/2, c-Jun, 
and STAT3) 
[57] 
Kaempferol-3-O-[2″,6″-di-O-Z-p-
coumaroyl]-β-D-glucopyranoside 
and derivatives 
CV-B3  In vitro Replication N/R [59] 
HRV-1B  In vitro Replication N/R [59] 
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Luteolin CV-A16 In vitro Replication Inhibition of viral RNA synthesis [55] 
 Poliovirus In vitro Replication N/R [56] 
Myricitrin CV-A16 In vitro Replication N/R [66] 
Pachypodol (RO 09-0179) 
CV In vitro Early replication 
Interference with viral replications between the 
uncoating and RNA synthesis stage 
[53] 
Poliovirus In vitro Late replication Blocked the synthesis of positive-strand RNA [51] 
 HRV  In vitro Early replication 
Interference with viral replications between the 
uncoating and RNA synthesis stage 
[53] 
Prunin Enteroviruses A and B 
In vitro 
and in 
vivo 
Translation and 
replication 
Inhibition of IRES activity and protein synthesis [68] 
Quercetin 
Encephalomyocarditis 
virus (EMCV) 
In vivo 
Indirect: Immune-
mediated infection 
control 
Activation of macrophages [4] 
 Mengo virus In vivo 
Indirect: Immune-
mediated infection 
control 
Activation of macrophages [4] 
 HRV In vitro 
Transcription and 
translation 
Reduction in endocytosis of virus and 
phosphorylation of Akt (effector of 
phosphoinositol 3-kinase). Repression of interferon 
and interleukin-8 response resulted in lower viral 
RNA and capsid protein production. 
[50] 
 HRV In vivo 
Indirect: Immune 
mediated infection 
control 
Suppression of viral immune mediators [50] 
RO 09-0298 CV-B1 In vivo N/R N/R [53] 
Sakuranetin HRV-3 In vitro Replication 
Antioxidant activity through inhibition of viral 
adsorption 
[62] 
Structures of flavonoids are provided in Supplementary Materials Table S1.
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3. Flavonoids that Target EV-A71 
Hand, foot and mouth disease (HFMD) is a global childhood infectious disease. It is 
predominant in Asia, with annual outbreaks ranging from two to three million cases. EV-A71 is one 
of the main etiological agents of HFMD, prevalent in children under the age of 6 years. EV-A71 
belongs to the Picornaviridae family and is classified as a non-enveloped RNA virus. The 7.4 kb 
genome of EV-A71 encodes four structural viral proteins (VP1 to VP4) and seven non-structural 
proteins (2A to 2C and 3A to 3D). These structural and non-structural proteins are generally being 
considered for designing effective antiviral agents against EV-A71. 
The life cycle of EV-A71 initiates with binding to host receptors such as SCARB2, vimentin and 
annexin 2. Once attached, the virus enters into the cell through endocytosis and uncoating starts in 
an endosome. Thereafter, the translation of mRNA and polyprotein processing occur. Human hnRNP 
A1 is an interaction partner of viral internal ribosome entry site (IRES) whereas hnRNP A2 is highly 
similar to hnRNP A1. Upon interaction of IRES with hnRNP A1 and hnRNP A2, the viral translation 
process is activated. Structural and non-structural viral proteins are formed via cleavage by 2A and 
3C proteases. This is followed by the replication and assembly of viral RNA into the capsid, 
maturation of viral particles and release of virus from the cells [69]. 
Many flavonoids have been studied to identify their potential as antiviral agents against EV-A71. 
The majority of the flavonoids studied demonstrated the antiviral activity by interference with the 
EV-A71 replication cycle (Figure 1). However, a few flavonoids have been reported to exert their 
antiviral activity by immune mediation (Figure 2). Examples of flavonoids with antiviral activities 
against EV-A71 are discussed.
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Figure 1. The antiviral activity of flavonoids in the life cycle of EV-A71. Flavonoids are reported to exhibit antiviral activity against EV-A71 and they are categorized 
according to the mechanism of inhibition at different stages of the virus life cycle. NR: not reported (Flavonoids that affect uncoating, assembly and release of EV-A71 
are not reported). HnRNP = heterogeneous nuclear ribonucleoproteins, IRES = internal ribosome entry site, IFN = interferon, JAK = janus kinase, TYK = tyrosine kinase, 
and STAT = signal transducer and activator of transcription proteins. 
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Figure 2. Inhibition of molecular signaling pathways involved in EV-A71 infection by flavonoids. Flavonoids are classified according to their ability at the molecular 
level to inhibit signaling pathways involved in EV-A71-induced apoptosis, inflammation and infection associated cytokine production. GDP = guanosine diphosphate, 
GTP = guanosine triphosphate, RAF = rapidly accelerated fibrosarcoma, MEK/MAPK = mitogen-activated protein kinase, ERK = extracellular signal-regulated kinase, 
SRSF/MnK2a = serine/threonine-protein kinase. JNK = c-Jun N-terminal kinase, ASK = apoptosis signal-regulating kinase, PEG = prostaglandins, COX = 
cyclooxygenase, and FasL = Fas ligand.
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3.1. Apigenin 
Apigenin is a flavone that has been tested for its antiviral potential against Fuyang and BrCr 
strains of EV-A71. It was able to reduce infection at the inhibitory concentration (IC50) of 10.3 μM. 
Apigenin inhibited EV-A71 infection by suppressing viral internal ribosome entry site (IRES) activity. 
Apigenin was found to disrupt the viral RNA association with hnRNP A1 and A2 proteins [70]. 
Moreover, apigenin was found to inhibit cellular apoptosis by caspase-3 cleavage, which is 
considered as a prime process to release viral progeny. It is also a known scavenger of reactive oxygen 
species (ROS) and was found to reduce infection-induced ROS generation in EV-A71 damaged cells. 
Furthermore, it decreased the cytokine levels involved in infection. Apigenin was confirmed to 
inhibit the activation of the c-Jun N-terminal kinase (JNK) pathway required for the replication 
process and release of progeny EV-A71. Another downstream p38 MAP kinase signaling pathway 
was found to be partially inhibited by apigenin. All these inhibitory mechanisms were suggested to 
suppress viral infection [71]. 
In a recent study by Dai et al. (2019), apigenin exhibited potent antiviral activity against EV-A71 
genotype C4 strain in vitro and in vivo. It was able to reduce the cytopathic effect to 50% at the 
concentration of 24.74 μM in 293S cells. Moreover, apigenin significantly reduced viral RNA and 
protein synthesis in vitro. When evaluated for its potential to protect newborn BALB/c mice from 
intracranial lethal challenge with EV-A71, apigenin was found to protect mice at the dose of 50 mg/Kg 
with 88.89% survival rate. Significant improvement in clinical scores and body mass were also 
observed in the treatment group as compared to the control group [72]. 
3.2. Baicalin 
Baicalin is a flavone reported to inhibit the BrCr-Tr strain of EV-A71 in post-infection assays with 
an IC50 of 4.96 μg/mL. Baicalin was shown to inhibit 75% viral infection at 8 h post-infection. 
Inhibition by baicalin at early stages of infection was due to a decrease in mRNA and protein levels 
of 3D polymerase. Moreover, it was also demonstrated that baicalin reduced the expressions of FasL 
and caspase-3, hence inhibiting EV-A71 induced apoptosis in Rhabdomyosarcoma cells (RD). 
Additionally, it was identified to inhibit proinflammatory cytokines by the reduction in NF-κB p65 
expression [73]. 
3.3. Chrysin and Its Derivative 
Chrysin is a flavone widely found in leaves, fruits, and vegetables. Chrysin and its ester 
(diisopropyl chrysin-7-yl phosphate) were evaluated against the clinical isolate EV-A71 Shzh-98 and 
were found to inhibit the viral replication process by blocking the activity of the 3C protein. Chrysin 
ester was found to be the more potent inhibitor of 3C protein than the parent chrysin. The activity 
was predicted in silico by simulation and was confirmed by in vitro protease inhibition assays. These 
flavonoids were able to decrease the production of the viral capsids, infectious virions and RNA of 
EV-A71 [74]. 
3.4. Fisetin 
Fisetin, a flavonol, was reported to possess antiviral activity against the clinical isolate EV-A71 
CMUH01 with an IC50 of 84.5 μM. Fisetin was able to inhibit the enzymatic activity of recombinant 
3C protease of the virus in a cell-based assay. To further confirm its activity in vitro, antiviral assays 
were performed in RD cells. Fisetin was found to block the cleavage activity of 3C and thereby 
inhibited the viral replication [75]. 
3.5. Formononetin 
The isoflavone formononetin was tested against several isolates of EV-A71 including BrCr, H, 
JS-52 and Shzh 98. Inflammatory pathways such as ERK, p38, JNK, MAPK are usually upregulated 
in EV-A71 infections and help in viral reproduction. Formononetin was shown to act on the MAPK 
pathway and reduced the activation of the downstream regulator of infection-induced inflammation 
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mediators, prostaglandin E2 (PEG2) and cyclooxygenase 2 (COX2). This, in turn, reduced the viral 
infection. Moreover, it also suppressed the signaling cascade of the ERK, p38 and JNK pathways to 
bring down the infection [76]. 
In another study, formononetin was found to inhibit EV-A71 strains G082, SH12-036 and SH12-
276. Formononetin was able to inhibit attachment and entry of EV-A71 in Vero cells. To further 
evaluate the exact target, the virus was passaged with increasing concentrations of formononetin and 
sequenced after the 10th passage. A common mutation causing K58T in VP4 was observed and this 
mutation was able to confer viral resistance towards formononetin. This resistance was further 
confirmed by the absence of K58T mutation in the wild type virus. The mutant virus was evaluated 
for attachment in Vero cells and the K58T mutation was found to inhibit viral attachment. It was 
hypothesized that formononetin could possibly cause an overall conformational change in the viral 
capsid [77]. 
Formononetin was also evaluated for its antiviral potential against EV-A71 subgenotype C4 
strain in 239S cells. It exhibited antiviral activity with an IC50 of 12.5 μM and significantly reduced 
viral replication and protein synthesis. It also protected newborn mice with a survival rate of 75% 
and significantly improved clinical score and animal body weight at a dose of 10 mg/Kg [72]. 
3.6. Hydroxyflavone and Its Derivatives 
The hydroxyflavones are synthetic molecules, the core structure of which is also a backbone of 
flavonols. Wang et al. (2014) predicted that 7-hydroxyflavone and its phosphate ester diisopropyl-
flavon7-yl phosphate were able to inhibit the activity of 3C protease of EV-A71 in silico. They further 
evaluated in vitro potential of these flavonoids as antivirals against Shzh-98 isolate of EV-A71. It was 
found that 7-hydroxyflavone and diisopropyl-flavon7-yl phosphate both inhibited virus-induced 
cytopathic effect in RD cells with an IC50 of 23.45 and 13.63 μM, respectively. In addition, both 
flavonoids significantly reduced viral protein synthesis [78]. 
3.7. Kaempferol 
The flavonol kaempferol was reported to inhibit the EV-A71 clinical isolate Chuh-050530-5. 
Kaempferol treated cells were observed to reduce virus yield by 6 log units 24 hpi. Kaempferol was 
able to exert its action through induction of trans-factors such as the far upstream element-binding 
proteins (FUBP) and hnRPs. These trans-factors were identified to bind the highly conserved 5` UTR 
region of the virus genome and attenuated the viral infection. Moreover, it also disrupted the activity 
of IRES by an overall change in the composition of the trans-factors. This resulted in reduced viral 
infection by inhibition of translation and replication [79]. 
Kaempferol was found to inhibit EV-A71 subgenotype C4 strain with an IC50 of 52.75 μM. It 
significantly reduced RNA copy number and protein synthesis 16 hpi. Newborn BALB/c mice were 
also protected from lethal challenge with the virus with 50 mg/Kg of kaempferol. The clinical score 
and body weight were found to be similar to that of the solvent treated group (negative control) [72]. 
3.8. Luteolin and Its Derivatives 
Luteolin is one of the examples of flavonoids that acted at an early step of the EV-A71 
(subgenotype C4b) replication cycle by post-attachment inhibition of the virus. The IC50 was found 
to be 10 μM [55]. Moreover, when luteolin was tested against the prototype BrCr strain and the 
Fuyang0805 isolate of EV-A71, it was able to prevent virus-induced ROS generation, cellular 
apoptosis and inflammatory cytokine production such as IL-6 and CCL5 [71]. In another independent 
study, Dai et al. (2019) showed that luteolin exhibited similar inhibition patterns with an IC50 of 13.5 
μM. It was identified to reduce viral replication and protein synthesis. Moreover, in the murine 
model, it showed 91.67% protection of newborn mice at a dose of 10 mg/Kg [72]. 
Eupafolin, a methoxy derivative of luteolin, was also found to inhibit EV-A71 with an IC50 of 1.39 
μM in an independent study. It was shown to inhibit IL-6 and chemokine RANTES which were 
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upregulated during the in vitro viral infection. This inhibition resulted in the down-regulation of 
ERK, activated protein-1 (AP-1) and STAT3 mediated inflammatory signaling pathways [57]. 
3.9. Penduletin 
Penduletin is a methylated flavonol abundantly found in the leaves of Laggera pterodonta. The 
compound was tested for its antiviral activity against EV-A71 strain GZ-08-02. The flavonoid was a 
potent inhibitor of EV-A71 with an IC50 of 0.17 and 0.20 μM in Vero and RD cells, respectively. 
Mechanistic studies revealed that penduletin specifically inhibited the production of infectious RNA 
viral progeny. Moreover, it was also able to reduce VP1 expression in post-infection assays, 
suggesting its ability to halt protein synthesis during viral replication process [80]. 
Penduletin also exhibited potent in vitro and in vivo antiviral activity against EV-A71 
subgenotype C4 strain. The IC50 was found to be 0.63 μM in 293 S cells and 66.67% newborn BALB/c 
mice survived the lethal challenge with EV-A71 when mice were treated with 5 mg/Kg dose of 
penduletin [72]. 
3.10. Peracetate Pulicarine 
Peracetate pulicarine is one of the less-studied flavonoids against viruses. It is a methoxyphenyl 
acetate, a derivative of a flavonoid which was found to possess anti-EV-A71 activity in a recent 
screening of a flavonoid library. The antiviral activity of pulicarine was associated with inhibition of 
the 3D polymerase expression in EV-A71 replication process [81]. 
3.11. Prunin 
Prunin is a flavanone glycoside recently found to be potent antiviral against enteroviruses A and 
B including clinical isolates and strains of H, B5 and C4 genotypes of EV-A71. Prunin was able to 
suppress the activity of IRES and disrupted protein and RNA synthesis with an IC50 of 115.3 nM. It 
was further evaluated in the murine model using newborn BALB/C mice. Prunin was able to protect 
from the lethal challenge of EV-A71 (strain 41) with a 100% survival rate at the doses of 3 mg/Kg and 
10 mg/Kg per mice. Apart from suppression of IRES activity in vitro, prunin successfully protected 
mice from the infiltration of immune cells and inflammation of tissues. Moreover, prunin was also 
able to reduce viral antigen in hindlimb muscles of mice [68]. 
3.12. Quercetin and Its Derivatives 
Quercetin has been found to possess broad-spectrum antiviral activity by several mechanisms. 
When tested against EV-A71, quercetin was able to target the post-attachment stage of EV-A71 
infection in vitro by disrupting viral RNA [55]. In another study, quercetin was predicted to interact 
with catalytic residues of the 3C protease and could inhibit the activity of viral the 3C protease in 
silico. To further confirm the findings, quercetin was evaluated for its antiviral activity using the SK-
EV006/Malaysia/97 isolate of EV-A71. The IC50 of 8.8 μM was observed in Vero cells and 12.1 μM in 
RD cells. Quercetin was also investigated for its anti-apoptotic potential against virus-induced cell 
death. Quercetin was able to prevent the viral spread induced by apoptosis, thus making it a dual 
action antiviral agent [82]. 
Rutin is another glycoside flavonol derivative of quercetin. It was identified as antiviral against 
EV-A71 using the recombinant 3C protease screening assay. To confirm its activity in vitro, rutin was 
tested against EV-A71 strain CMUH01 (B5). Rutin was able to inhibit the replication stage of infection 
with an IC50 of 110 μM [75]. In another study, rutin was found to reduce the infectivity of the C4 
subgenotype EV-A71 with an IC50 of 200 μM. The anticipated mechanism was recognized as the 
suppression of the MEK1-ERK signaling pathway [83]. Direct inhibition of the 3C protease and 
interference with inflammatory pathways were assumed to contribute to the reduction of virus titres. 
Quercetagetin, a synthetic derivative of quercetin, was identified to inhibit the RNA replication 
machinery and viral translation. The flavonoid was found to reduce the activity of the 3D polymerase 
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in vitro [81]. Similarly, chrysosplenetin, a methylated derivative of quercetagetin, was identified to 
potently inhibit EV-A71 by reducing the production of viral RNA and proteins [80]. 
Quercetin and its methoxy derivative isorhamnetin and chrysosplenetin were evaluated for their 
in vitro and in vivo potential as antivirals against EV-A71 (subgenotype C4). Quercetin and 
chrysosplenetin displayed potent antiviral activities in vitro with an IC50 of 1.2 μM and 0.68 μM, 
respectively while isorhamnetin showed inhibition with an IC50 of 60.7 μM. All three flavonoids 
reduced RNA and protein synthesis in vitro. In the same study, these flavonoids were evaluated to 
identify their protective effect in mice from lethal challenge of EV-A71. Isorhamnetin was found to 
confer the best protection at the dose of 10 mg/Kg with 100% survival while quercetin could only 
protect 50% of the animals using the same dose. Despite being the most potent antiviral amongst the 
three flavonoids when tested in vitro, chrysosplenetin was the least effective in vivo. Only 30% of the 
animals survived after treatment with 5 mg/Kg of chrysosplenetin. All three flavonoids were able to 
improve the clinical score and bodyweight of the treated animals [72]. It should be taken into 
consideration that in this study, the route of virus inoculation was intracranial while flavonoids were 
administered by intraperitoneal (IP) route. This difference of injection routes could result in varying 
efficacy of flavonoids to cross the blood-brain barrier and potentially protect mice from virus. In vivo 
antiviral activity of different flavonoids against EV-A71 has been summarized in Table 4. 
3.13. Flavonoids Isolated from Scutellaria Baicalensis Georgi 
Flavone derivatives such as mosloflavones, norwogonin and oroxylin A are abundant in 
Scutellaria baicalensis Georgi. These flavones were isolated as pure compounds and were reported to 
inhibit early stages of EV-A71 replication with an IC50 of 37.72, 31.83 and 14.19 μg/mL, respectively. 
All three flavonoids were able to limit replication process, leading to inhibition of viral protein (VP2) 
synthesis. However, oroxylin was found to possess superior activity as compared to mosloflavones 
and norwogonin. Furthermore, these flavonoids were evaluated for their potential to inhibit viral 
attachment and entry. None of these flavonoids were found to be involved in the inhibition of 
attachment or entry of the virus in Vero cells [84]. 
3.14. Flavonoids with Unknown Mechanisms of Action against EV-A71 
There are more examples of flavonoids that were reported to inhibit EV-A71. However, the 
mechanisms by which they modulated the infectivity of EV-A71 are still unknown. Examples include 
nobiletin, morin hydrate, myricetin, taxifolin, diosmetin, dihydromyricetin [85], hesperidin [79], thio 
flavones [86] and galangin [55]. 
4. Structure–Activity Relationship among Potential Antiviral Flavonoids against EV-A71 
Flavonoid classes differ from each other by various substitutions particularly phenolic or 
hydroxyl (OH) groups on its flavan nucleus. Flavonoids that have successfully accounted for antiviral 
activity against EV-A71 mostly belong to the flavonoid sub-classes flavonols and flavones. Flavones 
are dual fused aromatic rings (A and C) with an extension of a benzene ring (B) at position 2 of ring 
C (Figure 3) [87]. The skeleton “ring A fused with ring C” has previously reported to possess antiviral 
activity against the dengue virus NS2B-NS3 complex [88]. Moreover, hydroxylation on ring A, 
particularly on positions 5 and 7, was found to be favorable for antiviral activity against the influenza 
A virus [89]. Based on previous findings, it can be expected that the same structure could attribute 
towards antiviral activity against EV-A71. 
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Figure 3. General chemical structure of flavone nucleus. 
It can be observed that the anti-EV-A71 flavonoids with methylation have drastically improved 
the antiviral activity such as in the case of chrysosplenetin, eupafolin, penduletin and pruning (Table 
3). Moreover, presence of methoxy substitution at the position 7 of ring A, along with hydroxyl or 
methoxy group at position 6 rendered higher activity with lowest IC50 values (chrysosplenetin, 
eupafolin, penduletin) amongst all evaluated flavonoids. Prunin, a glucoside of naringenin, having 
large glucose moiety at position 7 instead of methoxy substitution, interestingly showed potent 
antiviral activity as well. From these examples, it can be speculated that positions 6 and 7 of ring A 
require bulky group substitutions in order to possess potent activity against EV-A71. Possible 
interactions between different substitutions and EV-A71 could be studied in silico to determine the 
nature of bonds involved in antiviral activity. It must be noted the antiviral activity of flavonoids was 
evaluated against specific EV-A71 genotype/subgenotype. It is unknown if there is a broad spectrum 
of antiviral activities against other EV-A71 genotypes/subgenotypes. 
A C
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Table 3. In vitro antiviral activities of flavonoids against Enterovirus A71. 
Flavonoid Structure 
EV-A71 Strain * 
(Genotype/Subgenotype) 
Antiviral 
Activity/IC50 
Cytoxicity/CC50 Reference 
Apigenin 
 
Fuyang 0805 
(C4a) 
10.3 μM 
 
79.0 μM 
(RD cells) 
[70] 
Fuyang0805 
(C4a) 
BrCr (A) 
Not reported 
>200 μM 
(RD and Vero 
cells) 
[71] 
Baicalin 
 
BrCr (A) 4.96 μg/mL 
823.53 μg/mL 
(RD cells) 
[73] 
Chrysin 
Ester of chrysin (CR) 
SHZH-98 
(C4) 
C = 13.86 μM 
>200 μM 
(RD cells) 
[74] 
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CR = 24.12 μM 
>200 μM 
(RD cells) 
Chrysosplenetin 
 
GZ-08-02 
(Accession # FJ360545) 
0.17 μM 
(Vero cells) 
18.27 μM 
(Vero cells) 
[80] 
0.20 μM 
(RD cells) 
13.90 μM 
(RD cells) 
Eupafolin 
 
Not reported 
0.44 μg/mL 
(RD cells) 
355.87 μg/mL 
(RD cells) 
[57] 
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Fisetin 
 
CMUH01 
(B5) 
85 μM 
>1000 μM 
(RD cells) 
[75] 
Formononetin 
 
 
SHZH-98 (C4) 
JS-52 (C4) 
H 
BrCr (A) 
3.45–3.95 μM 
17.87  ±  8.51 μM 
11.11  ±  9.23 μM 
6.47  ±  4.40 μM 
149.38 μM 
(Vero cells) 
198.80 μM 
(SK-N-SH cells) 
[76] 
Galangin 
 
C4b Not reported Not reported [55] 
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Hesperetin 
 
Cmuh-050530-5 
(Accession # HM807310) 
Not reported 
>50 μM 
(RD cells) 
[79] 
Hesperidin 
 
Cmuh-050530-5 
(Accession # HM807310) 
Not reported 
>50 μM 
(RD cells) 
[79] 
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Hydroxyflavone (HF) 
and its phosphate 
ester 
 
SHZH-98 
(C4) 
23.45 μM 
>200 μM 
(RD cells) 
[78] 
 
 
SHZH-98 
(C4) 
13.63 μM 
>200 μM 
(RD cells) 
[78] 
Kaempferol 
 
Cmuh-050530-5 
(Accession # HM807310) 
Not reported 
6 log reduction 
at 24 hrs 
>50 μM 
(RD cells) 
[79] 
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Luteolin 
 
C4b 10 μM 
148.02 μM 
(RDS cells) 
[55]  292.00 μM 
(RD cells) 
178.65 μM 
(Vero cells) 
Fuyang0805 (C4a) 
BrCr (A) 
Not reported [71] 
157 μM 
(Vero cells) 
200 μM 
(RD cells) 
Penduletin 
 
GZ-08-02 
(Accession # FJ360545) 
0.17 μM 
(Vero cells) 
111.46 μM 
(Vero cells) 
[80] 
0.37 μM 
(RD cells) 
74.18 μM 
(RD cells) 
Peracetate pulicarine 
5865/sin/000009 
(B4) 
Not reported. 
>20 μg/mL 
(RD cells) 
[81] 
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5511-SIN-00 
(B5) 
2.5 Log 
reduction 
Prunin 
 
EV-A71 
clinical isolates, EV-A71 strains 
H, B5 and C4 genotypes 
 
115.3 nM 
2715 nM 
(RD cells) 
[68] 
Quercetagetin 
5865/sin/000009 
(B4) 
Not reported. 
>20 μg/mL 
(RD cells) 
[81] 
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5511-SIN-00 
(B5) 
3.5 Log 
reduction 
Quercetin 
 
SK-EV006/Malaysia/97 
(Accession # AB469182) 
12.1 μM 
(RD cells) 
>200 μM 
(RD and Vero 
cells) 
[82] 
8.8 μM 
(Vero cells) 
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Rutin 
 
CMUH01 
(B5) 
110 μM 
>1000 μM 
(RD cells) 
[75] 
Thio flavones 
(Multiple) 
4b 
7d 
7i 
8b 
9b 
 
4b = R1 = OCH3, R2 = H 
SHZH-98 
(C4) 
4b = 16.9 μM 4d = 29.23 μM 
[86] 
7d = 8.27 μM 7d = 107.34 μM 
7i = 39.63 μM 7i = 133.15 μM 
8b = 100.86 μM 8b = 174.41 μM 
9b = 5.48 μM 
9b = 23.75 μM 
(Vero cells) 
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7d = R1 = 4-methoxyphenyl,R2 = H 
7i = R1 = CH3, R2 = Cl 
 
8b = R = n-propyl 
 
9b = R1 = OH, R2 = H, R3 = OH, R4 = OH 
  
* Accession number is mentioned where genotype/subgenotype is not reported; IC50 is the inhibitory concentration of flavonoid required to cause 50% inhibition of virus; 
CC50 is the cytotoxic concentration of flavonoid required to cause 50% cell death. 
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Table 4. Antiviral activity of flavonoids against Enterovirus A71 in newborn mice. 
Flavonoid 
In vitro 
EC50 
(µM) 
Lethal Dose of Challenge 
Virus 
In Vivo Dose of 
Flavonoid 
Survival 
Rate 
Duration of Treatment Reference 
Apigenin 24.74 600,000 TCID50 50 mg/Kg 88.89% 
Once a day for 7 days, starting from 2 h post-
infection 
[72] 
Chrysosplenetin 0.68 600,000 TCID50 5 and 1 mg/Kg 30% 
Once a day for 7 days, starting from 2 h post-
infection 
[72] 
Formononetin 12.5 600,000 TCID50 10 mg/Kg 75% 
Once a day for 7 days, starting from 2 h post-
infection 
[72] 
Isorhamnetin 60.7 600,000 TCID50 10 mg/Kg 100% 
Once a day for 7 days, starting from 2 h post-
infection 
[72] 
Kaempferol 52.75 600,000 TCID50 50 mg/Kg 88.89% 
Once a day for 7 days, starting from 2 h post-
infection 
[72] 
Luteolin 13.5 600,000 TCID50 10 mg/Kg 91.67% 
Once a day for 7 days, starting from 2 h post-
infection 
[72] 
Penduletin 0.63 600,000 TCID50 5 mg/Kg 66.67% 
Once a day for 7 days, starting from 2 h post-
infection 
[72] 
Prunin 0.115 2 × 107 PFU 3 and 10 mg/Kg 100% 
Once a day for 7 days, starting from 1 or 6 h 
post infection 
[68] 
Quercetin 1.2 600,000 TCID50 10 mg/Kg 50% 
Once a day for 7 days, starting from 2 h post 
infection 
[72] 
Note: Flavonoids were administered into the newborn mice by the intraperitoneal route. 
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5. Limitations of Flavonoids as Antivirals against EV-A71 
Flavonoids are abundant in fruits and vegetables and therefore are considered as safe and non-
toxic for human consumption. However, the bioavailability of these flavonoids in their crude form is 
very poor. Use of isolated, purified or chemically synthesized small molecular weight flavonoids has 
increased prospects to reach the target. To further enhance the stability, solubility and improved 
systemic distribution, a nano-drug delivery system can be employed [90]. Despite possessing the 
potential to treat EV-A71 in vitro and in mice, flavonoids have failed to reach clinical trials. Some of 
the possible reasons could include infancy of in vivo studies on flavonoids against EV-A71 as there 
have been only two reports which were published in 2019, claiming absolute protection of mice by 
prunin and isorhamnetin [68,72]. Moreover, lack of long-term toxicity data on purified flavonoids 
contributes challenges to further progress these potential molecules to clinical trials. Another 
important factor could be the development of resistance by mutant viruses against these flavonoids. 
Like any other drug candidate, purified flavonoids require regulatory approval from the Food and 
Drug Administration (FDA) before it can be marketed as antivirals. Detailed pharmacokinetic, 
pharmacodynamics and long-term toxicology studies on these flavonoids are necessary before they 
can be offered as a therapeutic option. 
6. Conclusions 
Flavonoids such as penduletin, eupafolin, baicalin, luteolin, quercetin and chrysosplenetin have 
been shown to be antiviral agents against EV-A71 based on their IC50 values (<10 μM). These 
flavonoids were also found to be safe and non-cytotoxic to human cells as indicated by CC50 values. 
Flavonoids such as prunin could confer 100% protection of neonatal mice while luteolin showed 
91.67% protection against lethal challenges with EV-A71. However, flavonoids with higher IC50 
values can also serve as a potential antiviral against EV-A71. For instance, kaempferol and 
isorhamnetin exhibited higher IC50 in vitro but both conferred significant protection of mice from 
viral challenge. The flavonoids that have not yet been tested in vivo could be further evaluated to 
identify their effectiveness. 
Flavonoids, with their ability to target various stages of viral infection, are becoming a more 
focused topic to explore their potential as antivirals in the current era. Apart from their classical 
antioxidant properties, some flavonoids have been shown to inhibit viruses at the molecular level 
both in vitro and in vivo. In light of the current finding of the in vivo efficacy of some flavonoids 
against EV-A71, it can be concluded that flavonoids have great potential to be developed as 
therapeutic candidates against EV-A71. However, to make these flavonoids available as antivirals, a 
more in depth understanding of their pharmacological properties and clinical outcomes is warranted. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: Molecular 
structures of antiviral flavonoids. Structures of flavonoids discussed in Tables 1 and 2 are provided in 
supplementary Table S1.  
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